CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,103 enrolled
Drug / intervention
Pioglitazone/metformin hydrochloridedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02024971
NCT02024971N/ACompleted
CompareCT.gov

Metact® Combination Tablets Special Drug Use Surveillance Survey on Long-term Use for Type 2 Diabetes Mellitus

Takeda·observational·Posted Dec 31, 2013·Updated Nov 22, 2016

In Brief

An observational study evaluating Pioglitazone/metformin hydrochloride for Type 2 Diabetes Mellitus. Completed, enrolled 1,103 participants.

Detailed Summary

The purpose of this study is to investigate the safety and efficacy of long-term use of pioglitazone/metformin hydrochloride combination tablets in the routine clinical setting in patients with type 2 diabetes mellitus for whom therapy with pioglitazone hydrochloride combined with metformin hydrochloride is considered suitable.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 31, 2013
Enrollment StartJul 1, 2010
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 12.5 years ago

Interventions

Pioglitazone/metformin hydrochloridedrug

Pioglitazone/metformin hydrochloride combination tablets